Home » Topics » Regulatory » EMA

EMA
RSS

Signifor recommended by CHMP to treat patients with acromegaly

Sep. 29, 2014

EMA committee recommends European approval of Cyramza

Sep. 29, 2014

Harvoni recommended for the treatment of chronic hepatitis C

Sep. 29, 2014

EMA committee hands down positive opinion on Trulicity

Sep. 29, 2014

EMA committee recommends approval of Moventig

Sep. 29, 2014

EMA recommends ketoconazole for approval in Cushing's syndrome

Sep. 29, 2014

CHMP recommends approval of aclidinium bromide/formoterol fumarate

Sep. 29, 2014

Oxabact awarded E.U. orphan drug designation for short bowel syndrome

Sep. 25, 2014

EMA approves pediatric investigation plan for TiGenix's Cx-601

Sep. 9, 2014

European orphan drug designations for CER-001 in apoA-I and ABCA1 deficiencies

Sep. 3, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...